A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Clinical trial NCT00528333 · COMPLETED

Trial details

NCT number: NCT00528333
Sponsor: Seagen Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2007-09-01
Primary completion: 2010-08-01
Enrollment: 211

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.